The University of Colorado completes exclusive option agreement to commercialise eyesight medical device to medtech Galaxy Ophthalmics.
The University of Colorado has exported rights to commercialise an implantable medical device to tackle the effects of glaucoma to local medtech firm Galaxy Ophthalmics.
Glaucoma is the second leading cause of irreversible blindness on the planet, with over 60 million sufferers worldwide. It is a group of eye diseases that attack the optic nerve which can currently be tackled with surgeries which drain the eye’s inner fluid, and return a 50% failure rate after five years.
Colorado’s innovation allows doctors to have greater control of the drainage rate both during surgery and for months to years following it, improving patient outcomes.
Galaxy is now in the process of raising funding to conduct animal trials of the device whilst also seeking a co-development or licensing agreement to bring the treatment to market.
David Poticha of the CU Technology Transfer Office said: “The University is very excited about this agreement, and believes this partnership with Galaxy has great potential to benefit a patient population that needs alternative therapies beyond what’s currently available.”
